PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Completed

Conditions: Leukemia, Myeloid, Acute

First Posted Date: 2020-04-07

Last Posted Date: 2021-08-09

Lead Sponsor: Pfizer

Target Recruit Count: 32

Registration Number: NCT04337138

Locations: 🇺🇸
Pfizer Investigational Site, New York, New York, United States

A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC

Phase 3

Terminated

Conditions: Advanced Non-squamous NSCLC

Interventions: Drug: PF-06439535 (CN)
Drug: Bevacizumab-EU
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2020-03-27

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 8

Registration Number: NCT04325698

Locations: 🇨🇳
Affiliated Hospital of Hebei University, Baoding, Hebei, China
🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China

and more 1 locations

Study of Single and Multiple Ascending Doses of PF-07059013 in Healthy Adult Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-07059013

First Posted Date: 2020-03-26

Last Posted Date: 2022-01-28

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT04323124

Locations: 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Phase 2

Completed

Conditions: Nonalcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis With Liver Fibrosis

Interventions: Drug: PF-06865571
Drug: Placebo
Drug: PF-05221304

First Posted Date: 2020-03-25

Last Posted Date: 2025-03-21

Lead Sponsor: Pfizer

Target Recruit Count: 256

Registration Number: NCT04321031

Locations: 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
United Medical Doctors, Murrieta, California, United States
🇧🇬
DCC Mladost-M Varna OOD, Varna, Bulgaria

and more 283 locations

Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy

Completed

Conditions: Renal Cell Carcinoma

Interventions: Procedure: nephrectomy

First Posted Date: 2020-03-16

Last Posted Date: 2021-05-19

Lead Sponsor: Pfizer

Target Recruit Count: 618

Registration Number: NCT04309617

Locations: 🇺🇸
Duke University, Durham, North Carolina, United States

Besponsa Post Marketing Surveillance Study

Completed

Conditions: Hematologic Maligmancy

Interventions: Drug: Inotuzumab ozogamicin

First Posted Date: 2020-03-13

Last Posted Date: 2025-03-27

Lead Sponsor: Pfizer

Target Recruit Count: 108

Registration Number: NCT04307134

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Other: Placebo
Drug: PF-07081532
Drug: Clopidogrel

First Posted Date: 2020-03-12

Last Posted Date: 2024-02-05

Lead Sponsor: Pfizer

Target Recruit Count: 66

Registration Number: NCT04305587

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Qps-Mra, Llc, South Miami, Florida, United States

Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.

Phase 1

Completed

Conditions: Non-Small-Cell Lung Cancer
Pancreatic Cancer
Cachexia
Colorectal Cancer

Interventions: Drug: PF-06946860

First Posted Date: 2020-03-06

Last Posted Date: 2023-12-14

Lead Sponsor: Pfizer

Target Recruit Count: 11

Registration Number: NCT04299048

Locations: 🇺🇸
SCL Health Cancer Centers of Colorado - St. Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
🇺🇸
American Oncology Partners of Maryland, PA, Germantown, Maryland, United States
🇺🇸
Tallahassee Memorial Healthcare Cancer Center, Tallahassee, Florida, United States

and more 6 locations

Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B

Phase 4

Completed

Conditions: Hemophilia B

Interventions: Biological: Nonacog alfa

First Posted Date: 2020-02-27

Last Posted Date: 2022-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT04286412

Locations: 🇮🇳
Nirmal Hospital Pvt Ltd., Surat, Gujarat, India
🇮🇳
K.J. Somaiya Hospital and Research Centre, Mumbai, Maharashtra, India
🇮🇳
Christian Medical College and Hospital, Ludhiana, Punjab, India

and more 2 locations

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Phase 3

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy

Interventions: Other: Placebo
Genetic: PF-06939926

First Posted Date: 2020-02-24

Last Posted Date: 2025-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 122

Registration Number: NCT04281485

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Arkansas Children's, Little Rock, Arkansas, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States

and more 46 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy